Company intelligence / Profile preview

Cru Bio

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Cru Bio is a private biotechnology company focused on developing innovative therapies for kidney and related diseases. The company presents itself as being dedicated to preserving kidney health and building a pipeline of drug candidates for areas of high unmet need in nephrology. Publicly available information indicates that Cru Bio is led by experienced biopharmaceutical executives with backgrounds spanning kidney therapeutics, venture-backed company creation, and business development. As of the latest accessible company materials, Cru Bio has not publicly disclosed named pipeline assets, molecular targets, or clinical-stage programs.

Therapeutic areas: Nephrology
Industry: Biotech

Beyond the preview

Go deeper on Cru Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cru Bio.

Explore the full profile